Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 17; no. 8; p. 1035
• Main Authors: Jony, M Rasheduzzaman, Ahn, Sangzin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06-08-2024; MDPI
• Subjects: anti-tuberculosis; Bile; Clinical significance; COVID-19; Drug dosages; Drug interactions; drug-drug interactions; enzyme; Enzymes; FDA approval; Infections; Infectious diseases; Medical personnel; Metabolism; Mortality; Pandemics; Patients; Pharmaceutical industry; Pharmacodynamics; Pharmacokinetics; Review; RNA polymerase; Severe acute respiratory syndrome coronavirus 2; Toxicity; transporter; Tuberculosis; Viruses; United States > US; COVID-19; enzyme; anti-tuberculosis; drug-drug interactions; transporter
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph17081035

Most medications undergo metabolism and elimination via CYP450 enzymes, while uptake and efflux transporters play vital roles in drug elimination from various organs. Interactions often occur when multiple drugs share CYP450-transporter-mediated metabolic pathways, necessitating a unique clinical care strategy to address the diverse types of CYP450 and transporter-mediated drug-drug interactions (DDI). The primary focus of this review is to record relevant mechanisms regarding DDI between COVID-19 and tuberculosis (TB) treatments, specifically through the influence of CYP450 enzymes and transporters on drug absorption, distribution, metabolism, elimination, and pharmacokinetics. This understanding empowers clinicians to prevent subtherapeutic and supratherapeutic drug levels of COVID medications when co-administered with TB drugs, thereby mitigating potential challenges and ensuring optimal treatment outcomes. A comprehensive analysis is presented, encompassing various illustrative instances of TB drugs that may impact COVID-19 clinical behavior, and vice versa. This review aims to provide valuable insights to healthcare providers, facilitating informed decision-making and enhancing patient safety while managing co-infections. Ultimately, this study contributes to the body of knowledge necessary to optimize therapeutic approaches and improve patient outcomes in the face of the growing challenges posed by infectious diseases.